MHRAsafety guidance65% confidence
ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (melanoma) as Immunocore.
Regulatory Analysis
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-mediated angioedema does not respond to standard treatment.
Supporting Context
- Therapeutic area
- Oncology · Immune-Mobilizing T-cell Receptors
- Sub-indication
- Melanoma
Related signal: Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma